Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Cassava Sciences (SAVA) stock is on the rise Wednesday after revealing interim results from a recent Alzheimer's disease clinical trial. The post SAVA Stock: 12 Things for Investors to Know About Cassava Sciences as Shares Soar appeared first on InvestorPlace.

SAVA Stock: 12 Things for Investors to Know About Cassava Sciences as Shares Soar

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

The biotech's experimental Alzheimer's treatment could be a game changer.

Why Cassava Sciences Stock Skyrocketed Today

Cassava Sciences (NASDAQ: SAVA) shares are trading higher Tuesday after the company announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer's disease. "Patients' cognition and behavior scores both improved following six months of simufilam treatment, with no safety issues," according to the company.

Why Cassava Sciences Stock Is Surging Higher Today

The stock price of Cassava Sciences Inc (NASDAQ: SAVA) has increased over 150% today. This is why it happened.

SAVA Stock Price Increases Over 150%: Why It Happened

Shares of Cassava Sciences soared as much as 221% Tuesday after the biopharmaceutical company announced upbeat data on its leading drug candidate for the treatment of Alzheimer's disease. The stock price of the Austin, Texas-based company surged toward an almost 10-year high, on track to close to its highest level since June 2011.

Cassava Sciences soars over 200% to 10-year high on positive Alzheimer's treatment data (SAVA)

Shares of Cassava Sciences Inc. more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments announced upbeat results from a study of its treatment for Alzheimer's disease. The stock shot up 173.6%, enough to pace all gainers trading on major U.S. exchanges, and to put it on track for the highest close since June 2011.

Cassava Sciences stock nearly triples toward a 10-year high after upbeat data on Alzheimer's treatment

Interim analysis of the first 50 patients to complete 6 months of sumifilam treatment came sooner than we expected. The results are nothing short of phenomenal and historic - "Patients' cognition and behavior scores both improved following six months of sumifilam treatment, with no safety issues"

Historic Day In Alzheimer's As Cassava Sciences' Sumifilam Improves, Not Just Stabilizes, Cognition And Is Again Shown Safe

It's been 20 days since we released a report on Cassava Sciences saying it could be the best-performing stock of 2021. The stock has already doubled, but we think this is just the beginning.

Positive Data On Eli Lilly's Alzheimer's Drug And Many Other Catalysts Suggest Cassava Sciences' Run Is Just Getting Started

IDEXX Laboratories

Royal Philips

These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.

The 3 Best Healthcare Stocks to Buy for 2021

Anavex Life Sciences

Biohaven Pharmaceutical Hld

Biogen

Eli Lilly

Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers.

Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73

Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company's Phase 3 development of simufilam for Alzheimer's disease. Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company's Phase 3 development of simufilam for Alzheimer's disease.

Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer

As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).

Cassava Sciences' (SAVA) Shares March Higher, Can It Continue?

Future References to Lead Drug Candidate for Alzheimer's Disease Will Be Simufilam Future References to Lead Drug Candidate for Alzheimer's Disease Will Be Simufilam

USAN Modifies Lead Drug Candidate's Chemical Name to ‘Simufilam'

AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the pricing of its previously announced underwritten public offering. The Company is offering 9,375,000 shares of its common stock, par value $0.001 per share, at a price to the public of $8.00 per share. In connection with the offering, the Company has also granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock offered in the public offering.

Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock

A public offering is weighing on the biophama's shares today.

Why Cassava Sciences Stock Is Retreating Today

AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it is commencing an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. The Company expects to grant the underwriters a 30‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering.

Cassava Sciences Announces Proposed Public Offering of Common Stock

Aurinia Pharmaceuticals

Heron Therapeutics

This biotech titan should be a top player on the merger and acquisition scene next year.

Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy

AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today reported financial results for the third quarter ended September 30, 2020.

Cassava Sciences Reports Third Quarter 2020 Financial Results

Cassava Sciences (SAVA) is in the news Wednesday after announcing data from a recent clinical trial concerning Alzheimer's disease. The post Cassava Sciences News: Why SAVA Stock Is Soaring 24% Today appeared first on InvestorPlace.

Cassava Sciences News: Why SAVA Stock Is Soaring 24% Today

Alzheimer's Patients Treated with Sumifilam Show ed a Statistically Significant (p

Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer's Disease

Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.

What's in the Cards for Cassava (SAVA) This Earnings Season?

A positive note from an investment bank about the biotech caught investors' attention.

Why Cassava Sciences Is Bolting Higher Today

Cassava's Alzheimer's disease drug candidate is turning heads.

Why Cassava Sciences Stock Crushed It in September

Cassava Sciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

News for Cassava Sciences Inc Stock (SAVA)